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Immunosuppressive activity and side effects of deflazacort versus
6-methylprednisolone in renal transplantation. A. Elli, R. Rivolta, P.
Palazzi, M. Parenti, P. Bonara, F. Quarto DiPalo, C. Zanussi, Clinica
Medica 10, Università di Milano, Milan, Italy. In a prospective,
double-blind randomized trial the immunosuppressive activity and side
effects of two different steroid molecules, 6-methylprednisolone (6MP)
and deflazacort (DFZ) (an oxazolinic derivative of prednisolone), have
been compared in renal transplantation. Forty new cadaver renal
transplants were allocated to a treatment with DFZ or 6MP. The
equivalent dose of steroid expressed as 6MP (ratio 6MP/DFZ = 2:3)
was 30 mg on 5th day, tapered to 8 mg on 180th day and, subsequently,
12 mg at alternate days until 12th month. Differences were not observed
in age, sex, HLA matching and in mean dose of CSA and AZA given in
the trial period. Rejections episodes, infectious diseases, lymphocyte
subsets, oral glucose tolerance tests, creatinine, cholesterol and tryglic-
erides plasma levels were evaluated on month 1, 3, 6, and 12 after renal
transplantation. In the DFZ group 7 rejection episodes were observed
and 10 in 6MP group (P:NS), all reversible except one in a patient
treated with 6MP. Infectious complications were less in DFZ patients
(DFZ 3 vs. 6MP 8; P:NS). Creatinine plasma levels were lower in all
treatment periods in DFZ group (P = 0.001). DFZ treated patients
showed a reduction of the CD4 lymphocytes (helper T cells, P = 0.05)
and a significant decrease in CD47CD8 ratio (P = 0.01). No differ-
ences were observed in CD3 (total T cells), CD3DR (activated T
cells), CD19 (B cells) and CD57 (natural killer cells) lymphocyte
subsets between the two groups. From the third month on serum
cholesterol (P = 0.01), tryglicerides (P = 0.01) and body weight
variations (P = 0.05) were significantly less in DFZ treated group. Oral
glucose tolerance tests were better up to the sixth month in the DFZ
group (P = 0.02). This difference disappeared when the steroid treat-
ment was taken on alternate days. In conclusion, DFZ is a steroid
molecule which possesses less metabolic side effects on glucose and
lipid metabolism and better immunosuppressive activity than 6MP.
These properties are evident also when DFZ is given at a maintenance
dosage and make it particulary useful in chronic steroid therapy when
the problem of side effects is greatest. The use of this compound could
represent an alternative to the late withdrawal of steroid treatment that
in renal transplantation is associated with a 20% to 30% incidence of
rejection episodes.
Post-biopsy renal transplant arteriovenous fistulas (AVF): Effectiveness
of duplex scanner (DS). B. Malfi, G.P. Segoloni, G. Triolo, C. Cogno, C.
Massara, C. Rabbia, A. Vercellone, Nephro-Urology Institute of the
University of Torino; Radiology Department of (he Emergency Ward,
S. Giovanni Hospital, Torino, Italy. Post-biopsy AVF in renal trans-
plant may progressively increase in magnitude leading to deterioration
of glomerular filtration. To evaluate the incidence of post-biopsy AVF,
154 patients undergoing 239 biopsies were evaluated by ATL MK 500,
ATL MK 600, Ultramark 8 and Hitachi 590 color DS. Analysis of phase
frequency and amplitude information were performed in real time in
connection with doppler module with pulse wave operating with sector
transducers at 90% or convex transducers (3.5 to 5 MHz) connected to
a single video. Analysis was performed both on the main vascular axis,
on its principal diramations and on renal parenchyma, particularly on
the biopsied pole. DS analysis was considered positive in the presence
of remarkably altered flow velocities and turbolence at the parenchymal
level, and of increased arterial and venous diastolic velocities on
efferent or afferent vessels respectively. AVF of various size were
diagnosed in 7 patients (2 AVF in 1 pt). Overall, the incidence of AVF
was 2.6% of all eco-driven biopsies performed at our Center using 16/15
Sterylab Bio-cut needles (6 AVF/239 biopsies). In all patients with AVF
arteriograms allowed to figure out the size and the entity of blood
draining off the cortex. No AVF was first diagnosed by angiography
performed for other clinical reasons in post-biopsy transplants who
resulted negative at an earlier DS analysis. Thus DS seems to be the
first choice to rule out post-biopsy AVF. For its panoramic view and
detection of flow disturbances over a wide field, color ultrasound
analysis is the ideal approach to the diagnosis of AVF.
Epstein-Barr virus reactivation after renal allograft: Correlations with
immunoglobulin abnormalities. F. Giacchino, C. Merlino, G.P. Seg-
oloni, M. Rotunno, A. Manzione, A. Vercellone, Chair of Nephrology
and Microbiology institute of the University, Turin, italy. Primary
Epstein-Barr virus (EBV) infection is not frequent after renal allograft,
because the majority of the patients develop anti-EBV antibodies
before transplantation; reactivation EBV infection is more frequent at 3
times greater than in the general population. At longer intervals after
transplantation, EBV-related lymphoproliferative disease has been
noted in renal transplant patients. Immunoglobulin (Ig) abnormalities
have been reported in transplant patients, in some cases associated with
lymphoproliferative disease and lymphomas. Sera from 80 renal trans-
plant patients (48 males, 32 females, mean age 41.2 11 years), 37
treated with cyclosporine A (C5A) and low doses of steroids (P), 7 in
conventional therapy and 36 in triple therapy (CsA+P+ azathioprine),
were studied to assess the influence of EBV infection on Ig abnormal-
ities. Antiviral capsid antigen (VCA) IgG and 1gM, anti-EB nuclear
antigen (EBNA) IgG and anti-early antigen (EA) IgG were evaluated by
the ELISA technique. A reactivation EBV infection was defined by the
absence of anti-VCA 1gM, with the presence of anti-VCA IgG and
anti-EBNA IgG. Ig light chain measurement was used as a means of
typing monoclonal Igs by single radial immunodiffusion. A K/lambda
ratio of 0.8 to 1.2 was considered normal. All patients were seropositive
at the beginning of the study. Alteration in the K/lambda ratio was
observed in 44/80 patients (55%) [36 patients with only K/lambda
alteration, 8 patients with monoclonal component (4 IgGK, 2 IgAK, I
IgMK, 1 1gM lambda)]. Reactivation EBV infection was found in 31
patients (38.7%), without any correlation with sex, age of the patients or
Ig alteration. Reactivation EBV infection was less frequent in patients
on triple therapy than in those treated with double treatment (P
0.002). In 8 cases with monoclonal component precocious reduction of
immunosuppressive therapy was made, without any deterioration in
their immunological surveillance. None of the patients have developed
the lymphoproliferative syndrome so far.
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Results of corticosteroids withdrawal in children with renal transplan-
tation. L. Ghio, A. Edefonti, A. Mocciaro, M. Giani, D. Colombo, L.
Berardinelli, A. Vegeto, L. Guerra, A. Tarantino, Clinica Pediatrica Ii,
Servizio Dialisi, Universitâ di Milano; Divisione Nefrologia, Divisione
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Chirurgia del Trapianti, Ospedale Maggiore di Milano, Milan, Italy.
Withdrawal of corticosteroids would be of great advantage in children
submitted to renal transplantation (Tx), in order to avoid growth
impairment and aesthetic disfiguration. For this purpose, methylpred-
nisolone (MP) was stopped 6 months after Tx in 29 children trans-
planted from 1986 to 1989, mean age 10.4 3.4 years, who had
previously been treated with combined immunosuppressive therapy:
cyclosporin A (CsA) + MP. Creatinine clearance, height standard
deviation score (HSDS) for chronological age, weight for height index
(Will), were recorded at the time of Tx (TO), MP withdrawal (Ti), I
year after MP withdrawal (T2) and at the last evaluation (T3). We were
able to stop MP in 24 out of 29 children. No death occurred and the
"crude graft survival" was 97%. Rejection rate was 48% in the first 6
months after Tx and 29% in the period aft/er MP withdrawal. Currently
20 of 29 children (69%) succeded in remaining on CsA alone by a mean
of 27.3 15 months after MP withdrawal. The other data are as follows:
TO TI T2 T3
Creatinine 87.8 19.3a 83.9 9.W' 80.8 9.7
clearance
ml/min/
1.73 in2
1-ISDS —3.4 1.& —3.7 2.0l —2,9 2.2 —2.5 2.4
WHI 0.95 025b 1.09 013b 1.04 0.I4 1.01±0.1
a P = NS; b P < 0.01; ' P < 0.001
In conclusion, an immunosuppressive protocol based on CsA alone,
after the initial phase of Tx, allows a better growth and nutrition, with
a similar renal survival and function in comparison with MP + CsA
treatment. Therefore it is a logical solution before trying other treat-
ment (GH).
Controlled trial of cyclosporine monotherapy versus double therapy
with subsequent steroid withdrawal at six month in renal transplant
recipients. L. Cristinelli, S. Sandrini, G. Setti, F. Scolari, P. Scaini, R.
Maiorca, Institute of Nephrology of University of Brescia and Depart-
ment of Nephrology, Spedali Civili, Brescia, Italy. In this trial we
compared two different therapeutic schedules for the prophylaxis of
acute rejection in first cadaveric renal transplant recipients. Study
group (A) (29 pts) was treated with cyclosporine (Cs) alone i.v, (5
mg/kg/day) for 3 days, then double daily oral dosage starting from 12
mg/kg/day, subsequently adjusted to achieve Cs blood trough levels
between 100 and 200 ng/ml (specific monoclonal RIA method). After the
third episode of acute rejection in the first six months, patients
maintained steroid (MP) in association with Cs. Control group (B) (28
pts) was treated with double therapy during the first six months: Cs as
in A, MP at the daily dosage of 20 mg for 4 days, 16 mg from day 5 to
day 90, 12 mg from day 91 to day 150, 8 mg from day 151 to day 180.
Starting from day 181 MP was tapered and totally withdrawn at day 240.
Patients who had no acute rejection episodes continued treatment with
Cs alone; those with acute rejection, after antirejection treatment
according to our usual schedule, continued MP in association with Cs.
Follow-up in both groups was of 21 8 months. We observed 3 deaths,
only in the B group during the first six months (1 suicide, I Pneamo-
cystis carinii pneumoniae, 1 road accident). After 24 months patient
survival was 100% in A and 92% in B (F: NS). Three grafts were lost in
A and 2 in B; after 2 years no difference in graft survival was observed
(A-90% vs 8-86%). During the first six months the number of acute
rejection episodes was higher in the group A (74 episodes, i.e. 2.6/pt)
than in the B group (47 episodes, i.e. 1.7/pt) (P C 0.005). MP total
dosage in the first six months was lower, but not statistically different,
in A (3837 1581 mg) than in B (4352 1055 mg); Cs daily mean
dosage, during the same period, was similar in the two groups (A: 5.1
I vs B 5.4 1.6mg/kg/day). After the sixth month we observed 8 acute
rejection episodes in 23 pts in group B and 12 episodes in 26 pts in group
A. At the end of follow-up the percentage of patients treated with MP
was significantly higher in A (84%) than in B (47%) (P C 0.001). Serum
creatinine levels were significantly higher at 3rd and 6th month in A (1.6
0.5 and 1.6 0.6 mg/dl) vs. B (1.2 0.6 and 1.2 0.4 mg/dl; P C
0.05). No difference was observed in the two groups regarding dyslip-
idemia and antihypertensive therapy. In conclusion, in our experience
Cs monotherapy from the beginning in regard to MP withdrawal at the
sixth month is not advantageous for the high incidence of acute
rejection, reduced graft function and for the absence of clinical advan-
tages.
Controlled randomized trial of steroid withdrawal after six months in
renal transplant recipients treated with cyclosporine results at 4 years. L.
Cristinelli, U. Setti, S. Sandrini, F. Scolari, P. Scaini, R. Matorca,
Institute of Nephrology of University of Brescia and Department of
Nephrology, Spedali Civili, Brescia, Italy. In this randomized prospec-
tive study, we report the effects obtained 4 years after steroid (MP)
withdrawal at the sixth month in first cadaveric kidney transplant
patients (pts) initially treated with Cs and low doses of MP. Sixty-six pts
were randomized at the 6th month in the two groups: control group (A)
(31 pts) continuing the maintenance dosage of MP (8 mg/day) and study
group (B) (35 pts) reducing MP by 2 mg/week until complete withdrawal
at the 210th day. Group B pts who had no acute rejection episodes
continued treatment with Cs alone (group Bl). Those pts with acute
rejection (group 82), after antirejeetion treatment according to our
usual schedule, continued MP tapered in 6 weeks to the maintenance
dosage of 8 mg/day. In 48 months of follow-up after transplantation, no
statistically significant difference in patient survival was observed
between group B (99%) and group A (88%). During the trial two pts
died, both in the group A: 1 of myocardial infarction, 1 of cerebral
stroke, Three grafts were lost in A and 4 in B; group A (7 1%) and group
B (73%) revealed no statistically significant difference in graft survival.
During the trial there was a statistically significant difference in acute
rejection episodes (B: 21 episodes in 19 pts vs. A: 3 episodes in 3 pts;
P C 0.005). At the end of follow-up the probability of acute rejection
was significantly higher in B (54%) than in A (10%; P C 0.001. At the
same time serum creatinine levels were higher, but not significantly, in
B2 (15 pts; 1.5 0.4 mg/dl) compared to A (27 pts; 1.3 0.4 mg/dl) and
81(16 pts; 1.3 0.5 mg/dl). The percentage of pts with MP-relatable
complications remained stable in groups A and B2, whereas in group Bi
there was a marked reduction of acne, facies lunaris, hirsutism,
hypertension (60% vs. A-83% and B2-94%), hypercholesterolemia (13%
vs. A-44% and B2-44%), hypertrygliceridemia (33% vs. A-48% and
B2-62%), absence of cataract (0 vs. A-59% and B2-52%) and tendonitis
or Achille's tendon rupture (0 vs. A-3% and 82-6%). In conclusion, 4
years after steroid withdrawal there were no differences in patient and
graft survival; creatinine serum levels were not significantly different in
the two groups of patients; 46% of patients could be maintained without
steroid and steroid-relatable complications. In spite of the great number
of rejection episodes steroid withdrawal appears to be advantageous.
Immunosuppressive therapy and renal functional reserve in kidney
transplant recipients. R.M. Fagugli, A. Selvi, L. Fedeli, U. Buoncris-
tiani, U.O. Nefrologia e Dialisi, U.O. Medicina Nucleare, Perugia,
Italy. We studied renal functional reserve (RFR) in 21 kidney transplant
recipients after an oral protein load (I g/kg) by radioisotopie method
(EDTA Cr51). Patients consisted of 3 groups according to immunosup-
pressive therapy: cyclosporine and steroid (N = 7), cyciosporine-
azathioprine and steroid (N = 7), azathioprine and steroid (N 7).
Transplantation age was between I and 10 years, serum ereatinine was
<2 mg/dl, and patients had good blood pressure with or without
therapy. We observed two groups: one without RFR having basal GFR
of 113.6 48.1 mI/mm, and another with RFR (15.1 14.8%) having
basal GFR significantly lower (64.8 25.6 mI/mm, P c 0.001). The
transplantation age of these groups was not different (5.7 2.5 vs. 4.7
3.1 years). In the group with RFR 22% of patients were in therapy
with azathioprine, 33% with eyclosporine, and 44% with azathioprine
and cyclosporine. In the group without RFR 41% of patients were in
therapy with azathioprine, 33% with cyclosporine, 25% in combined
therapy. Cyclosporinemia was not different in the two groups (330.5
140 vs. 447.2 120.1 ng/ml). In all patients there were 14 cases of
hypertension (66.6%), 8 with RFR (57.2%) and 6 without RFR (42.8%).
Basal GFR of hypertensive patients was 87.4 44.05 mI/mm and in
normotensive was 103.4 57.1 mI/mm (P = NS). Hypertensive patients
with RFR had a GFR of 67 28.26 mI/mm, and those without RFR had
a GFR of 114.67 48.68 mI/mm. Transplantation age was not different.
Patients in therapy with azathioprine were hypertensive in 57.1% of
cases (N = 4), and those in therapy with cyclosporine azatioprine
were hypertensive in 71.4% of cases (N = 6 4). From these data we
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can report two groups in kidney transplant recipients with good organ
function: the first with RFR and the second without RFR and in a
hyperfiltration state. If we analyze the rule of immunosuppressive
therapy on GFR and RFR we cannot report connections between them,
as there isn't between transplantation age or hypertensive state and
hyperfiltration and absence of RFR. In fact, of the 12 patients without
RFR 58% of cases (N = 7) were in therapy with cyclosporine, 58% had
a transplantation age >5 years (N = 7), and 50% were hypertensive (N
6); relative risk (Fischer's test) was not significant. Therefore, the
causes, independently from prognostic significance, must be searched
in other factors, like quantity and composition of protein diet in these
type of patients.
Bone status in renal transplant patients. P. Gilli, P. Valpondi, A.R.
Cavallini, P.L. Bedani, C. Orzincolo, B. Bagni, Divisione di Nefrolo-
gia, Clinica Ostetrica, Medicina Nucleare, Servizio di Radiologia,
Arcispedale S. Anna, Ferrara, Italy. To evaluate long-term bone
abnormalities, 44 patients (pts) were studied 84.4 55.8 (months 5 to
195) after kidney transplantation. Twenty-seven pts had normal GFR
and 17 had serum creatinine >1.5 < 3 mg%; 24 were treated with
steroids, azathiopnne and CsA, 20 with steroids and azathioprine. In all
pts were performed: (a) skeletal computed radiography; (b) double
x-ray absorptiometry (DXA) of the spine from L1 to L4 in AP projection
with Hologic DQR 1000. Bone mineral density was expressed in g/cm2.
The severity of osteopenia was defined by z score and t score; the latter
identifies the fracture risk; (c) determination of Ca, P, Mg in serum and
urine and of serum intact PTH, caltitonin, l.25(OH)2D3; BGP,
AP, and free testosterone. The radiological examination demonstrated:
osteopenia in 40/44 pts; osteonecrosis of the femoral head in 4 pts, of
the condyle of femur in I, of the humeral head in 1, of one of the carpal
bones in 3; acroosteolysis and subperiosteal reapsorption in 3 pts;
carpal bone cysts in 9 pts. The bone densitometry showed osteopenia (z
score <—1) in 28 pts, serious osteopenia (z score <—2) in 16, risk of
fracture (t score <—2) in 21. Osteopenia increased with the duration of
renal transplantation (r = 0.4); it seems related to PTH values (r =
0.35), even in pts with normal GFR (r = 0.42); a protective effect could
be induced by calcitonin levels (r = 0.34) and, in osteopenic pts, by
1 .25(OH)2D3 levels (r = 0.46). In conclusion, a significant decrease of
bone mass was present in about 50% of transplant pts, probably related
to steroid administration. In thee pts, preventing and treating measures
need to be considered.
Ca modulate erythropoiesis in polycthemic kidney transplant pa.
tients (PKTP). S. Carozzi, M.G. Nasini, A. Cantaluppi, M. Salit,
Nephrology and Dialysis Unit, St. Paul's Hospital, Savona, Italy;
Baxter, Round Lake, Illinois, USA. Polycythemia is a common com-
plication of kidney transplantation; its pathogenesis, however, is un-
known. Recent in vitro studies indicate that the culture medium's Ca
concentration conditions the response to erythropoietin (EPO) of bone
marrow non-adherent mononuclear cells (BM NAMC) which have
specific receptors for I ,25(OH)2D3. To further study this problem we
evaluated in 10 PKTP: (I.) In vitro: (a) erythroid colony (BFU-E and
CFU-E) growth from BM NAMC in the presence of increasing doses of
EPO; (b) BFU-E and CFU-E development in the presence of increasing
doses of Ca + alone, Ca plus 1, 25(OH)2D3 or Ca plus the calcium
antagonist Diltiazem; (2.) in vivo: (a) BM NAMC cytoplasmic (cy)
Ca concentration; (b) plasma EPO levels. Values were compared
with those of 10 non-polycythemic kidney transplant patients (NPKTP)
and 10 normal controls (NC). Results: (I.) In vitro in PKTP the BFU-E
and CFU-E growth was higher than in NPKTP, in the presence of both
low and high doses of EPO. There was a direct relationship between
BM NAMC cy Ca and BFU-E and CFU-E growth. In PKTP, NPKT
and NC the addition of Ca + to the medium induced a dose-dependent
rise in BFU-E and CFU-E development; 1, 25(OH)2D3 potentiated
these effects, while with Diltiazem colony development decreased; (2.)
in vivo: in PKTP the BM cy Ca ÷ concentration was higher than in
NPKTP and NC, while plasma EPO levels were not different. Conclu-
sions: These data indicate that cy Ca modifications in BM erythroid
cells play a role in the regulation of normal erythropoiesis as well as in
the pathogenesis of EPO-independent erythrocytosis seen in some
kidney transplant patients.
Simvastatin treatment of hypercholesterolemia in renal transplant
recipients. V. Franco, T. Lusenti, G. Lindner, F. Soliani, A. Stefani,
P.P. Borgatti, Division of Nephrology and Dialysis, Arcispedale S.
Maria Nuova Reggio Emilia, Italy. Complications of atherosclerotic
vascular disease are frequent in kidney graft recipients. The
hyperlipidemia, and particularly elevation of total and LDL-choles-
terol, is an important risk factor of cardiovascular morbidity and
mortality of this patient population. Simvastatin, a specific inhibitor of
HMG-Co-A reductase, has been used to treat (20 mg once a day)
hypercholesterolemia of 7 kidney graft recipients with stable graft
function. All the patients (4 men and 3 women, mean age 54 6) had
immunosuppression with CsA, met hy 1-prednisolone and azathioprine.
Five patients had been treated for more than two years and two patients
for six months without adverse effects. There were no alterations of the
serum chemistries examined, except for CPK that increased even
within the normal range. Total cholesterol decreased by 21% (288 26
to 226 15 mg%, P < 0.001), LDL-Chol by 33% (203 24 to 135 11
mg%, P < 0.001), APO B by 20% (122 26 to 95.6 14 mg%, P <
0.01). APO A levels remained practically unchanged (—0.8%). The ratio
of APO B/APO A fell from 0.86 0.3 to 0.6 0.2 (— 19%, P < 0.05).
Triglicendes decreased by 6.8% (203 14 to 172 48 mg%) and
HDL-Chol had a slight increase not statistically significant (51.7 12 to
57.8 15 mg% + 12%). We concluded that simvastatin at dosage of 20
mg daily is an effective and well-tolerated drug for correcting hyperlip-
idemia of renal transplant recipients.
Renal Na handling in primary hyperparathyroidism (PHP). G. Co-
lussi, C. Airaghi, M.E. De Ferrari, G. Rombolâ, Division of Nephrol.
ogy and Dialysis, Ospedale Niguarda-Ca' Granda, Milan, Italy. Severe
hypercalcemia inhibits tubular Na reabsorption and predisposes to
extracellular fluid (ECF) depletion; moreover, PTH inhibits proximal
tubule reabsorption of several solutes, including phosphorus (P), amino
acids, bicarbonate and possibly Na. Thus, in PHP both hypercalcemia
and increased plasma PTH levels are expected to interfere with tubular
handling of Na. We have investigated renal Na handling by lithium (Li)
clearance and/or free water clearance studies during maximal water-
induced diuresis in 36 PHP patients (surgically proven in 27) and 17
controls (C). PHP patients, compared to C, had slight hypercalcemia
(10.9 0.7 vs. 9.0 0.4 mgldl, P < 0.001), hypophosphatemia (2.3
0.5 vs. 3.4 0.5 mg/dl, P < 0.001) of renal origin (TmP/GFR 1.8 0.4
vs. 3.6 0.7 mg/dl), similar plasma Na (138.9 3.8 vs. 137.8 2.3, P
= NS), daily Na excretion (183 38 vs. 166 67 mEq/day, P = NS),
fasting FENa (0.96 0.65 vs. 1.05 0.46%; P = NS) and Na excretion
(1.4 0.8 vs. 1.4 0.8 mEq/literGFR, P = NS); however, after ECF
expansion with an oral water load (20 mI/kg body wt), both FENa and
Na excretion increased in PHP patients to higher levels than in C
(FENa) 1.8 0.9 vs. 1.1 0.5%, P < 0.005; NaE 2.4 1.2 vs. 1.45
0.61 mEq/liter GFR, P < 0.005). Distal delivery of glomerular filtrate
was higher in PHP patients, indicating reduced fractional reabsorption
of Na/fluid in the proximal tubule, when evaluated either as FELT in the
fasting state (24.8 6.3 vs. 19.4 7.5%, P < 0.05), or as "chloride
factor" (DDCI = CH,o + CCI/GFR) during maximal water diuresis (12.7
4.2 vs. 9.3 2.5, P < 0.01), or as "volume factor" (V1,'GFR =
maximal urine flow/GFR) during maximal water diuresis and furo-
semide administration (40 mg e.v., Bartoli et al, J Clin Pharmacol
23:56, 1983) (30.7 10.6 vs. 21.4 7.0%, P < 0.005). Post-proximal
solute reabsorption did not differ between PHP and C with all 3
methodologies. The effects of water load on segmental tubular Na
handling were evaluated by Li methodology: water load did not modify
proximal solute reabsorption (FEL) both in PHP (24.8 6.3 to 26.5
7.8%, P = NS) and C (19.4 7.5 to 17.4 4.3%, P = NS), however
post-proximal solute reabsorption, evaluated as (FELl — FECI)/FELI,fell in PHP after water load (from 94.6 3.2 to 88.8 6.8%, P < 0.01),
but not in C (from 93.2 2.5 to 91.5 4.2%, P = NS). Thus water
expansion appeared to increase Na excretion in PHP by an effect on
post-proximal tubular segments. FELl, DD1 and V1/GFR in PHP did
not correlate with total and ionized plasma Ca levels, plasma P levels
and TmP/GFR, and PTH(184); however, also PTH(184) was not corre-
lated with plasma P, TmP/GFR and FEE, suggesting a rather poor
correspondence between "dosage" of PTH and its biologic effects.
After parathyroidectomy (PTx), indices of post-proximal solute deliv-
ery fell to similar levels as in C: FELl 21.8 5.2% (P < 0.005 vs.
pre-PTx; P = NS vs. C), DDc1 10.8 3.3% (P < 0.05 and NS), V1/GFR
22.2 5.2% (P < 0.025 and NS). FENa and Na excretion after an oral
water load were no more higher than in C (1.1% and 1.5 0.9 Eq/dl
GFR, respectively, P = NS, vs. C), while daily Na excretion (194 62
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mEq/day) and fasting FENa (13 0.7%) remained unchanged. Body
weight increased significantly 3—6 months after PTx (from 66.6± 9.8 to
69.7 8.9 kg, P < 0.005) and plasma renin activity fell (from 2.14
1.28 to 1.08 0.85 ng/ml/hr, P <0.008): these observations suggest, as
a possibility, the occurrence of fluid retention in response to a state
ECF contraction present before PTx. Conclusions: in PHP proximal
tubule Nalfluid reabsorption is lower than in controls; this tubular
abnormality is associated with higher than normal Na excretion after
ECF expansion by an oral water load, secondary to a distal effect of the
load, and might be associated with ECF volume contraction. Abnormal
proximal tubule Na reabsorption indices in PHP are not correlated with
plasma Ca and PTH levels; however, they completely normalize after
successful PTx.
Thromboxane A2 (TxA2) regulates protein synthesis of cultured human
mesangial cells. P. Menè, A. D'Agostino, A. Taranta, F. Pugliese, G.A.
Cinoni, Department of Medicine, Division of Nephrology, and Institute
of Histology, University of Rome, Italy. The vasoconstrictor metabolite
of arachidonic acid, TxA2, stimulates contraction and regulates prolif-
eration of cultured glomerular mesangial cells. We studied the effects of
the stable mimetic, U-46619, on intrinsic and released proteins of
human mesangial cells. U-466l9 dose-dependently stimulated [3H]-
leucine incorporation into total, trichioroacetic acid-precipitable cell
proteins, from 7,441 247 to a maximum of 8,524 249 cpm/well at I
LM (P < 0.05). The effects of U-46619 were additive to those of serum.
Incorporation into membrane-associated and cytosolic proteins was
assessed by 1- and 2-D SDS-PAGE/fluorography of [35S]-methionine-
labelled cell homogenates. Labelling was enhanced in membrane and
cytosolic proteins with apparent molecular wt of 38 to 55 kD, both in
quiescent and cycling cells. Tubulin, but not actin biosynthesis was
specifically stimulated, as assessed by immunoblots of cytosolic soluble
proteins. U-46619 also increased labelling of 125 and 200 kD membrane
proteins in quiescent cells. On the contrary, the release of extracellular
proteins was markedly inhibited, as confirmed by [35S]methionine
labelling and immunoblots of collagen type IV. TxA2-regulated protein
synthesis may contribute to the structural and functional changes of
glomerular inflammation.
Heritability of erythrocyte sodium-lithium countertransport activity
(Na/Li CT) in IgA nephropathy (IgAN). A. Fabbri, R. Boero, E. Degli
Esposti, C. Guarena, G. Piccoli, M. Fusaroli, Department of Nephrol-
ogy, S. Maria della Croci Hospital Ravenna, and G. Bosco Hospital,
Torino, Italy. In a recent study we found that a high Na/Li CT could be
a marker of an increased risk of developing arterial hypertension, lipid
abnormalities and perhaps a more severe renal disease in IgAN. The
Na/Li CT, a marker of risk for essential hypertension, has a substantial
inheritable component. The aim of the work was to evaluate the
inheritance of Na/Li CT in IgAN by assessing this parameter in 19
patients with biopsy proven IgAN and in their 53 relatives (32 parents
and 21 siblings). The "familial" Na/Li CT was calculated as the mean
Na/Li CT of each patient's parents; in the absence of one parent this
datum was substituted by the mean of the siblings' values, A significant
correlation has been observed between "familial" and offsprings Na/Li
CT (r = 0.77, P < 0.001); no spouse-spouse correlation was found, The
Na/Li CT was higher in patients with proteinuria than in patients
without proteinuria (285 23 vs. 215 22, P < 0.05). Mean blood
pressure values too, although in normal range, were found significantly
higher in patients with proteinuria than in those without proteinuria
(93.5 2.5 vs. 85.8 2.3, P < 0.04). Conclusions: heritability of the
Na/Li CT is present in IgAN (environmental factors don't seem to play
a substantial role in the Na/Li CT). The increased Na/Li CT in patients
with proteinuria suggests that genetic factors could play a role in
favoring a non-immunological progression of IgAN.
Erythrocyte Na,Li countertransport In patients with primary IgA
nephropathy (IgAN). R. Boero, E. Degli Esposti, A. Fabbri, C.
Guarena, G. Forneris, F. Quarello, M. Fusaroli, G. Piccoli, Islituto di
Nefro-Urologia deli'Università, Ospedale G. Bosco, Torino, Ospedale
S. Maria delle Croci, Ravenna, Italy. A high erythrocyte Na,Li
countertransport (CNT) rate may be considered a genetic marker for
essential hypertension. Moreover, an abnormal CNT activity has been
found in type I diabetic patients with clinical evidence of nephropathy
and/or hypertension. It has been recently suggested that patients with
primary chronic glomerulonephritis, including IgAN, have an increased
genetic risk of hypertension. The aim of this study was to evaluate CNT
activity in erythrocytes from 52 patients with IgAN. Patients were
classified in three groups: (1) normotensive (PAD < 95 mm Hg) with Sr
1.4 mg/dl; (2) hypertensive with Sr  1.4 mg/dl; (3) patients with Sr
> 1.4 mg/dl. Results are reported as means and saM; statistical analysis
has been carried out with ANOVA.
Males/females
Group I Group 2 Group 3 ANOVA
15/8 14/6 7/2
Age years
CNT Na,Li
33 3
243 15
43 2
309 17
51 5
314 30
a,b
a,b
,'smol/liter
RBC/hr
Scr mg/dl
Proteinuria
0.96 0.03
0.36 0.07
1.12 0.04
1.64 0.35
2.03 0.24
2.85 0.57
a.c
abc
g/day
Triglycerides 115 12 187 32 198 38 a
mg/dl
Cholesterol 192 9 223 II 212 15 a
mg/dl
a P < 0.05 group I vs. group 2; b P < 0.05 group 1 vs. group 3;
" P < 0.05 group 2 vs. 3
Significant linear relationships have been found between CNT and
triglycerides (r = 0.397; P = 0.003), cholesterol (r = 0.449; P 0.0008),
BMI (r = 0.392; P = 0.004), S. (r = 0.28; P = 0.04), proteinuria (r =
0.305; P = 0.027). CNT was significantly higher in the 31 dyslipidemic
patients (cholesterol >200 mg/dl and/or triglycerides >172 mg/dl) than
in normolipidemic patients (313 13 vs. 233 16 mol/liter RBC/hr; P
= 0.0003). A high erythrocyte Na,Li countertransport rate may be a
marker of an increased risk of developing arterial hypertension, lipid
abnormalities, and perhaps a more severe renal disease in IgA nephrop-
athy.
Clinical, serologic and histologic features of ANCA-associated vasculi-
tides. R.A. Sinico, A. Radice, C. Pozzi, for the Italian Group of Renal
Immunopathology, Milano, Italy. To identify the main features of
ANCA-associated diseases, the clinical, serologic and histologic find-
ings were reviewed in 80 ANCA positive pts. The patients were divided
into two groups according to the antigen specificity: 55 had antibodies
(Abs) to myeloperoxidase (MPO) by ELISA and a P-ANCA pattern by
immunofluorescence (IF) (Group I); 25 had Abs to proteinase 3 (Pr3)
and a C-ANCA pattern (Group II). P-ANCA pts had a higher mean age
and a slight female prevalence when compared with group 11(61 vs. 47
years; 0.7:1 vs. 2.1:1, respectively). ENT, skin, nervous system, eye
involvement were significantly more frequent in Group II, whereas
there was only limited kidney disease in Group I. Lung involvement
was present in about 60% of pts in both groups. An involvement of 3 or
more organs was present in 83% of Group II pts but only in 38% of
Group I. Kidney disease was characterized in both groups by crescentic
necrotizing glomerulonephritis and rapidly progressive renal failure.
Leukocytosis, thrombocytosis, an increased CRP, increased serum
immunoglobulins were found at the same extent in both groups. Low
titer of rheumatoid factor was more frequent in Group II whereas
anti-nuclear antibodies were found in Group I. After a mean follow-up
of two years the patient and renal survivals were similar (about 70%).
Endogenous opiolds influence the insulin response to oral glucose load
in uremic patients. C. Zoccali, C. Sicuso, F. Cuzzola, S. Parlongo, A.
Curatola, Nefrologia e CNR Centro Fisiologia Clinica, Reggio Cal,
Italy. Endogenous opioids interfere with glucose homeostasis and a
compound of this class (Metenkephalin) reduces insulin sensitivity in
healthy subjects. Since plasma levels of endogenous opioids were
raised in uremic patients we have tested the hypothesis that retention of
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these substances affects insulin sensitivity in chronic renal failure. Ten
uremic patients (Cr > 5 mg/dl) underwent a standard oral glucose load
(75 g) on two occasions, at least 48 hours apart. Glucose load was
preceded either by an i.v. bolus injection (0.015 mg/kg) of Naloxone (a
specific antagonist of opioid substances) or by an equal volume of saline
(placebo) and followed by a continuous infusion of the same solutions
(0.03 mg kg/3 hr of Naloxone or 45 ml/3 hr of saline). The order of the
two experiments was randomized and balanced. The area under the
glucose curve (Placebo: 22137 929 arbitrary units, Naloxone: 21925
1437 arbitrary units) and the two experiments was virtually identical. In
contrast, the area under the insulin curve was significantly lower (P =
0.018) after naloxone (15247 4230 arbitrary units) than after placebo
(18568 4863). Furthermore, the slope of the relationship between
insulin and plasma glucose was lower (P = 0.06) with naloxone (1.1
0.3 pg/mg) than with placebo (1.4 0.3 gImg) which indicates that
antagonism of endogenous opioids increases insulin sensitivity. The
effect of naloxone on the insulin response tended to be related with
serum creatinine (r = 0.38). The data indicate that endogenous opioids
influence to an important extent insulin sensitivity in chronic renal
failure. Retention of these substances can be a factor contributing to
insulin resistance in uremic patients.
Low-dose intravenous calcitriol in the treatment of secondary hyper-
parathyroidism in hemodialysis patients. M. Gallieni, D. Brancaccio, P.
Padovese, D. Rolla, D. Lamperi, E. Paoletti, E. Moriero, P.L. Bedani,
E. De Paoli Vita/i, P. Gil/i, G. Colantonio, C. Giura, D. Martinelli, C.
Bronzieri, C. Grassi, B. Bagni, G. Tarolo, Divisioni di Nefrologia e
Dialisi, Ospedale S.Paolo, Milano; Ospedale S.Anna, Como; Ospedale
S.Martino, Genova; Arcispedale S.Anna, Ferrara; Ospedale Pred-
abissi, Melegnano, Servizi di Medicina Nucleare, Ospedale San Paolo,
Milano; Arcispedale S. Anna, Ferrara, Italy. Intravenous (i.v.) cal-
citriol is known to directly suppress PTH secretion and release. We
evaluated the effect of 4 months of treatment with low-dose i.v.
calcitriol on PTH levels in 83 hemodialysis patients. All patients
underwent standard bicarbonate or acetate dialysis; dialysate calcium
concentration was maintained at 3.5 mEq/liter. Initial calcitriol dose
was 0.015 gIkg body weight, and it was reduced in case of hypercal-
cemia or elevated Ca-P product. Seven out of 83 patients dropped out
during treatment. Among 76 patients who completed the study, 55
(76%) showed a highly significant decrease of intact PTH levels (from
793 to 411 pg/mI) and of alkaline phosphatase levels (from 302 to 225
U/liter, n.y. 60 to 170) after 4 months of therapy. No significant changes
in ionized calcium levels could be detected, even in responders (from
4.88 to 4.92 mg/dl). Mean serum phosphate was 4.95 mg/dl at the
beginning of study; it increased significantly after 4 months of treatment
in patients who showed a decrease of PTH levels, although it remained
within acceptable limits, below 5.5 mgldl; 28 of 76 patients (37%)
reduced the dose of calcitriol because their calcium-phosphate products
exceeded 60. Low-dose iv. calcitriol therapy for secondary hyperpara-
thyroidism in dialysis patients is safe and may be highly effective in
reducing serum PTH and alkaline phosphatase levels without significant
increases of ionized calcium concentrations.
Plasma endothelin and renal function during infrarenal aortic cross
clamping: Effect of dopamine vs. nifedipine infusion. F. Antonucci, M.
Bertolissi, L. Cab, F. Giordano, M. Travaglini, 0. Geatti, Department
of Nephrobogy, II Department of Anaesthesia, III Department of
Surgery, Department of Nuclear Medicine 0.C.Udine, Department of
Nephrobogy, University of Padua, Padua, Italy. In 10 patients who
underwent elective aortic surgery involving cross clamping of infrarenal
abdominal aorta for aneurysm or Leriche disease, we measured plasma
endothelin before the induction of anesthesia, at the beginning of the
clamping period, at the end of the clamping period and at the end of the
operation. Glomerular filtration rate (GFR) was evaluated the day
before and immediately after the end of the operation with 5tCr-EDTA
clearance. Intraoperatively creatinine clearance and urinary excretion
of prostaglandins were determined before, during and after aortic cross
clamping. Plasma endothelin was evaluated by RIA (endothelin-! ,2
assay system, Amersham) after chromatographic purification with
"Amprep 500". Thromboxane B2(Tx), PGE2,6K Fla were evaluated by
RIA method after solid-phase extraction using columns Sep-Pak Cl8,
Waters Associates. In all patients anesthetic management included
hemodynamic monitoring (Swan-Ganz catheter), intravenous anesthe-
sia (flunitrazepam, fentanyl, pancuronium) and ventilation with an 0/air
mixture. No patient received diuretics or vasoconstrictor agents. In 5
patients nifedipine (0.006-0.04 mg/kg/hr) was infused i.v. from the
isolation of aorta until the end of operation (group A), in 5 patients
dopamine (2 sglkg/m; group B). Preoperative mean values of GFR were
75 14 mI/rn/I .73 in group A, 78 10 in group B (P > 0.05). Mean
preinduction values of cardiac index (CI) and PCWP were not different.
In Group B CI did not show significant variations while in Group A
mean postclamping values of CI were significantly higher than pre-
clamping values (P < 0.05). No perioperative episodes of low cardiac
output were noted. Mean values of clamping time, duration of operation
and fluid balance were similar. Mean plasma endothelin concentrations
rose significantly during clamping and fell thereafter in both groups, but
mean values of Group B were higher (P <0.01) than the corresponding
values of group A. Urinary excretion of Tx, PGE2,6K Fla increased
significantly during clamping in both groups, but the rate PGE2+6k
FlaJTx during and after clamping was significantly (P < 0.02) higher in
group A than in B. Postclamping creatinine clearance decreased signif-
icantly in group B, increased in group A (P < 0.05). Postoperative mean
values of GFR were 80 12 rnl/m/l .073 in group A, 60 10 in B (P <
0.01). In conclusion: I) infrarenal aortic cross clamping enhances
endothelin production; 2) unlike dopamine, nifedipine can prevent the
vasoconstrictive effect of endothelin on the renal vascular bed.
Relationship between extracellular volume (ECV) expansion and serum
PTH. C. Zoccali, F. Mallamaci, F. Cuzzola, D. Leonardis, M. Pos-
torino, S. Parlongo, A. Curatola, L. Messineo, Nefrologia e CNR
Centro di Fisiobogia C/mica, Reggio Cal, Italy. PTH is a vasodilator
and reduces proximal sodium reabsorption and it has been suggested
that this hormone may participate in the physiologic response to ECV
expansion. We have studied the relationship between PTH and acute
volume expansion by saline (1 liter in 40 mm) in 21 patients with
essential hypertension. Serum PTH184 and arterial pressure (Dinamap
845) were measured in baseline conditions (B), at the end (E) and 30 mm
after saline infusion (S). At the zenith volume expansion (end-infusion)
there was a slight increase in arterial pressure (from 147 15/89 8 to
154 17/92 11 mm Hg). Such change was accompanied by a slight
but significant (P = 0.02) fall in plasma ionized Ca (from 1.12 0.12 to
1.09 0.11 mmol/liter) and by a marked PTH increase (from 35 12 to
59 21 pg/mI, P < 0.01). The PTH change was inversely related with
the degree of hemodilution (hematocrit change) (r =
—0.42, P = 0.06)
but independent of arterial pressure variations. In a second experiment
in 7 patients we infused the same volume of saline with the addition of
calcium in order to prevent hypocalcemia. In this study PTH remained
almost unmodified (B: 34 8 pg/mI, E: 28 7 pg/mI, 5: 34 8 pg/mI)
while arterial pressure changes were similar to those of the first study
(B: 136 12/87 12, E: 142 15/87 13 mm Hg). The data indicate
that PTH is very sensitive to ECV expansion induced by saline
infusion. Such phenomenon, which appears mediated by the slight
hypocalcemia caused by hemodilution, is of such consistency that it
may prove of value in the dynamic assessment of parathyroid function.
PTH, however, does not play a major role in the hemodynamic
response to ECV expansion.
Hemodialysis (HD) related porphyria cutanea tarda (PCT) treated with
erythropoietin (EPO). V. Piazza, F. Gal/i, G. Villa, F. Di Dio, S.
Segagni, G. Bovio, F. Poggio, L. Picardi, A. Salvadeo, Divisione di
Nefrologia, Fondazione Clinica del Lavoro, Pavia C/mica Medic 2,
Policlinico S. Matteo, Pavia, Italy. Sporadic cases of HD related PCT
have been reported; usual therapy is aimed to remove from the liver
iron either by phlebotomies or deferoxamine (DFO) and porphyrins by
chioroquine. These treatments may be ill-tolerated or ineffective in HD
patients. However iron stores may also be reduced by increasing
erythropoiesis with EPO therapy. In a case of HD related PCT we
evaluated DFO and EPO treatments. The patient, aged 65, with no PCT
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cases in his family, developed PCT while receiving HD. Increased
urinary uroporphyrins (UP) confirmed the diagnosis (272 g/24 hr, nv.
< 20). At that time hemoglobin (Hb) was 9.9 g/dl, serum ferritin (SF)
438 pg/liter. DFO was started (10 mg/kg i.v. at each dialysis) but did
not improve cutaneous symptoms and caused reduced visus. Also
anemia worsened, so after 30 sessions DFO was substituted with
beta-EPO (40 U/kg/dialysis i.v.). At therapy change Hb was 6.6 gIdl, SF
388 g/l, UP 143 g/24 hr. Within 3 weeks no new blisters formed, EPO
later improved anemia and reduced iron stores; the patient remained
free from PCT lesions (after 4 months: Hb 11 gIdl, SF 42 z/l, UP 69
jzg/24 hr). EPO could allow phiebotomies, unnecessary in our case for
the prompt healing of cutaneous symptoms, also in PCT patients on
chronic dialysis. Even if DFO improved other HD related PCT cases,
EPO offers an easier and safer way to remove iron from the liver. In
conclusion, we propose EPO as the drug of choice in HD related PCT.
Calcium increases plasma concentration of ANF in patients with
chronic renal failure. F. Mallamaci, C. Zoccali, F. Salnitro, Nefrologia
e CNR Centro Fisiologia C/mica, Reggio Cal, Italy. Although it is well
established that volume expansion and reduced renal clearance are the
main factors responsible for raised plasma ANF concentration in renal
failure, mechanism(s) regulating the release of this hormone in uremic
man are incompletely understood. Since it has been shown that calcium
raises plasma ANF in the rat, we have studied the influence of calcium
infusion (12 mg/kg/3 hr) on ANF release in 12 hemodialysis patients.
Patients were studied during the interdialysis day. Plasma ANF, ionized
calcium, arterial pressure (DINAMAP 845) and heart rate were mea-
sured in baseline condition (1 hr of supine rest) and during calcium
infusion (at 90 mm and 180 mm). Calcium infusion caused a consistent
increase in ionized calcium (from 1.18 0.20 to 1.41 0.25 mmol/liter,
P < 0.01) and in arterial pressure (from 136 19/79 15 to 151
16 mm Hg, P < 0.01/P 0.06) associated with a slight, baroreflex
mediated, bradicardia (HR: from 75 7 to 68 11 beats/mm, P = 0.04).
Interestingly, such changes were accompanied by a marked increase
(+33%, P <0.01) in plasma ANF from a baseline value of 80 35 pg/mI
to a final value of 105 63 pg/mi, However, ANF was poorly related
with the hemodynamic effects induced by calcium ANF vs. Systolic r
= 0.25 (NS), ANF vs. Diastolic r = 0.26 (NS), ANF vs. HR r = 0.23
(NS)I. The data indicate that mild hypercalcemia causes a clear cut
ANF increase in uremic humans. Such an effect, which is unrelated to
the effects of calcium on arterial pressure, may at least in part depend
on a direct influence of this cation on biosynthesis and/or secretion of
ANF in atrial cardiocytes.
A simplified approach to prescribing and monitoring dialysis sodium
balance. V. La Mi/ia, S. Di Filippo, G. Pontoriero, F. Locate/li,
Nephrology and Dialysis Unit, Hospital of Lecco, Italy. It has been
widely demonstrated that dialysate sodium concentration, and hence
sodium balance (JNa) plays an important role in maintaining cardio-
vascular stability during hemodialysis (HD). Prospective quantification
of JNa in HD has become possible with the development of various
kinetic models but, despite the availability of Na kinetic techniques
since 1980, few dialysis facilities base JNa on kinetic modeling
because of its mathematical complexity. We describe a simplified
technique for prescribing individualized JNat This technique is based
on the close relationship between INapw-NaD and FNapw-
lNapw that we found measuring INapw, FNapw and NaD during
387 HD treatments (INapw: initial Na concentration in plasma water;
FNapw: final Na concentration in plasma water; NaD: Na' con-
centration in dialysate). The relationship between sodium diffusive
gradient and change in sodium plasma water concentration is depicted
in the Figure. Furthermore, during 45 RD treatments, JNa was
determined by direct quantification according to: (VDIxNaDT) —
(VDOxNaDO), where VDI and VDO are respectively total inlet and
outlet dialysate volumes and NaDI and NaDO are inlet and outlet
dialysate Na concentrations. JNa was estimated simultaneously
according to: (ITBWxINapw) — (FTBWxFNapw), where ITBW and
FTBW were initial and final total body water volumes; INapw was the
"measured" Napw concentration at the beginning of RD treatment;
FNapw was the Napw concentration at the end of HD session
"predicted" with the formula depicted in Figure. We did not find
significant differences between the "measured" and "estimated" JNa
(—309.3 177.9 mmol vs. —305.4 137.0 mmol, P = NS). In
conclusion our technique, with only 2 Na measurements (INa+pw and
NaD), provides the clinician with a simple method for prescribing and
assessing JNa.
Effects of bolus the rHuEPO(E) on muscle blood flow in patients with
ERD. M. Buemi, F. Vitulo, C. Aloisi, N. Morabito, S. Ba/dan, M.
Privitera, A.L. Buemi, M. Cinquegrani, A. Allegra, N. Bonanno, N.
Frisina, Chair of Kidney Disease, Universitd Messina, Italy. It has
been postulated that absolute concentration of hematocrit may deter-
mine the blood pressure response to E. An alternative suggestion is that
increased hemoglobin concentration may elevate blood pressure indi-
rectly, thereby reversing hypoxia induced peripheral vasodilatation.
The aim of this study was to show that E can improve peripheral
vascular resistance directly. Maximal blood flow (MBF) on muscle of
leg were studied with xenon 133 clearance in 20 subjects (10 healthy
men and 10 patients with ERD) before and after intravenous adminis-
tration of E (100 UI/kg body wt). The study was repeated later after
treatment with nifedipine (N) or indomethacine (1) or verapamil (V).
Table. Clearance Xenon 133 (MBF ml/l00 g/min)
Before
E
After E
Alone
After E
+N
Controls 49 7 26 7 27 6
ERD 20 5b 14 3 5 a,b
After E
+1
After E
+V
Controls 29 6a 49 5
ERD 13 5a,b 21 3
P < 0.05 vs. controlsb P < 0.05 vs. Before £
These results show that E reduce MBF as in control as in patients with
ERD. N or I didn't modify effects of E, but V inhibited reduction of F
on MBF. It's possible to speculate that £ increases peripheral vascular
resistance by mechanism resulting of Ca + release from intracellular
stores.
In vivo intracellular pH recording by confocal laserscan microscopy. 0.
Capasso, M. Weinlich and R. Kinne, Max-P/wick Instilut fur System-
physiologic, Dortmund, Germany and Chair of Nephrology, First
Faculty of Medicine, University of Naples, Italy. Determination of
intracellular pH (pH1) is essential to understand the molecular mecha-
nism(s) involved in acid/base transport along the nephron. Since the
tubular structure is very heterogeneous it is recommended that pH is
measured at the level of single cell. To this end we have used confocal
FNa pw-INapw
mmotlitsr
Y —0.58X + 5.64
r— 0.75
N = 387
P < 0.001
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a
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a
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laserscan microscopy to record single cells pH1 regulation in vivo in
microperfused rat proximal convoluted tubule. Cells were loaded with
the pH sensitive, fluorescent dye 2',7'-bis (carboxyethyl)-5(6)-carboxy-
fluorescin (BCECF). Single cells could be distinguished within the
tubules. In in vivo experiments peritubular perfusion with NH4CI pulse
caused an immediate increase in fluorescence intensity by 23.3 4.5%.
Within a period of one mm the signal dropped back to baseline level.
The stop of perfusion lead to an immediate increase in intensity by 22.2
2.0% followed by recovery intensity back to baseline level observed.
The pattern of pH responses analyzed separately in various single
proximal tubule cells were similar, suggesting a homogeneous cell
population. Microperfusion, pH sensitive dyes and confocal laserscan
microscopy combines in a new non-invasive method to effectively
measure intracellular pH changes in individual cells of near surface
structures of the kidney.
Serum calcium oxalate saturation in patients on RDT for type 1
primary hyperoxaluria or other nephropathies. M. Marangella, C.
Vitale, M. Petrarulo, D. Cosseddu, F. Linari, Divisione di Nefrologia e
Dialisi, Ospedale Mauriziano Umberto I, Torino, Italy. To elucidate if
oxalate (Ox) retention in chronic renal failure (CRF) may induce CaOx
deposition in body tissues, we estimated the state of saturation with
CaOx (I3CaOx) on plasma ultrafiltrates from 28 patientson RDT, 5 of
whom with type 1 primary hyperoxaluria (PHI) and 23 with oxalosis-
unrelated CRF (non-PH 1), and from 8 healthy controls (HC) as well. Ox
was determined, by ion chromatography, on fasting blood in HC. In
RDT patients, Ox was assayed on samples from the whole dialyzate and
blood taken before, at the end, and at 48 hr from the end of a dialysis
session. l3CaOx was estimated by a computer system solving for the
interactions among 45 complex species. In HC plasma Ox was 3.8 1.5
jmol/1iter (range 1.4—5.8) and $c,c was 0.1 0.06. Non-PHI patients
had predialysis Ox of 49.8 14 mol/1iter and /3CaOX of 1.0 0.3. These
values were 2.5-fold decreased by dialysis and remained below satura-
tion at 48 hr from the end of the session. Predialysis Ox in PH 1 was 170
21 jsmol/liter and saturation was exceeded by more than threefold;
the samples were still supersaturated at the end of dialysis. /3CaOx was
closely related to Ox but not to Ca2 concentration, and was indepen-
dent of sex, age, body weight, or time on dialysis. From our data, in
non-PH! ESRD body fluids are often undersaturated with CaOx; this
should be inconsistent with progressive Ox imbalance and secondary
oxalosis. Conversely, body fluids from patients with PHi are virtually
always at risk for CaOx deposition.
Dopaminergic modulation of renal hemodynamic response to an oral
protein load in humans. A. Montanan, G. Ragni, M. Serventi, G.
Giucastro, C. Di Gennaro, P. Perinorto, A. Novarini, Istituto di
Se,neiotica Medica, Universird di Parma, Italy. To ascertain whether
the dopamine (DA) system is involved in the human renal changes
following an acute protein load (OPL), renal plasma flow (RPF, PAH
clearance), glomerular filtration rate (GFR, inulin clearance) and frac-
tional excretion of sodium (FENa%) were measured in 5 normal male
volunteers (age 27 to 32, body wt 62 to 84 kg) at baseline and at the third
hour after on OPL providing 1.0 g protein/kg body wt as bovine lean
meat. The same experiment was repeated after 10 to 21 days under
comparable conditions but with i.v. injection of 0.1 mg/kg body wt of
DA-blocker metoclopramide (MCP) at the beginning of OPL, followed
by infusion of 0.05 mg/kg . hr MCP throughout the entire experiment.
OPL alone produced a significant rise in RPF (583 21 SEM to 722 13,
P<0.001),GFR(118± 11 to 145 l2,P<0.001)andFEN,%(l.2±
0.2 to 1.6 0.2, P <0.02). With OPL + MCP, RPF increased much less
than with OPL alone (568 14 to 620 11, P < 0.02) and both GFR
(124 9 to 128 8, NS) and FENa% (1.3 0.2 to 1.2 0.3, NS)
remained unchanged. Our findings show that DA receptor blockade
with MCP is able to potently blunt renal responses to OPL. This
suggests that the DA system participates in renal vasodilation, hyper-
filtration and natriuresis following OPL in normal man.
Nifedipine but not captopril minimizes the negative renal effects of the
high osmolality contrast media in patients with reduced renal function. D.
Russo, R. Minutolo, E. De Rango, C. Libetta, U. Romano, V. Sepe, G.
Conte, 1st Department of Nephrology and 2nd Faculty of Medicine,
Naples, Italy. In this study we evaluated the protective role of
nifedipine and captopril in preventing the contrast-induced reduction of
GFR and RPF considering that: (1) low-osmolality (highly expensive)
media do not prevent renal changes; (2) calcium ions play a role in some
forms of toxic ischemic renal failure; (3) in a previous study, nifedipine
antagonized negative renal effects of an high osmolality medium in
patients with normal renal function; and (4) the renal renin-angiotensin
system could be involved in contrast-induced renal failure. Hospitalized
patients (N = 17; serum creatinine ranging from 1.5 to 3.5 mg/dl), who
needed i.v. pielography, were randomly assigned to one of following
groups: (A) iothalamate alone; (B) iothalamate + nifedipine (10 mg/os,
10 mm before medium); and (C) iothalamate + captopril (50 mg/os, 20
mm before medium). Basal measurements were made of GFR, RPF,
serum Na, K and Cl, urine output and urinary Na, K, and Cl excretion.
Measurements were repeated 20, 60, and 120 minuts after i.v. contrast
infusion. Basal measurements were not different along the groups. In
groups A and C, GFR and RPF were reduced (P < 0.05) after the
contrast, whereas they were minimally affected in group B. These
results show that the effects of the high osmolality medium on GFR and
RPF can be minimized by nifedipine. The inefficiency of captopril rules
out a role for renin-angiotensin system in contrast-induced acute
worsening of renal function.
SDS-PAGE patterns and polymers of albumin in proteinuria of lupus
glomerulonephritis. C. Bazzi, E. Sabadini, C. Petrini, V. Rizza, F.
Lavarda, E. Gandini, G. D'Amico, Division of Nephrology and Bio-
chemistry Laboratory, San Carlo Hospital, Milano, Italy. Characten-
zation of proteinuria has been performed by SDS-PAGE and by
immunoblotting with anti-albumin sera in 32 pts with lupus nephritis
(LN) (WHO class III 4 pts; class IV 18; class V 10). By SDS-PAGE
proteins bands can be classified as high (HMW: 150 kd), middle (MMW:
from 70 to 78 kd) and low (LMW: from 10 to 70 kd) molecular weights:
patterns of proteinuria can be categorized as pure glomerular (MMW
and HMW + MMW) and mixed glomerulo-tubular (HMW + MMW +
LMW 40-70 kd and HMW + MMW + LMW 10-70 kd). By immunoblot-
ting with anti-albumin sera polymers of albumin (PA) mainly of 100 and 120
kd can be detected in frozen urines. The SDS-PAGE patterns observed
more frequently in LN were HMW + MMW + LMW 40-70 kd (15 pts)
and HMW + MMW + LMW 10-70 kd (11 pts); the latter is associated
with higher levels of Sr (1.60 0.80 vs. 1.20 0.50 mgldl) and with lower
values of proteinuria (3.3 2.7 vs. 4.2 3.4 g/day). PA were present in
60% of LN pts: class III 0%; active class IV 100%; active class V 44%;
class IV and V in remission 0%. PA positive pts showed higher values of
Se,. (1.7 1.2 vs. 1.1 0.4 mgldl, P < 0.05), of activity index (10.4 5.4
vs. 6.0 2.9, P < 0.05) and of protemnuria (3.97 2.40 vs. 2.70 3.80
g/day, P = NS). In conclusion, in LN pts the mixed patterns of proteinuria
and the presence of polymers of albumin can be considered markers of
severity of renal involvement.
Collagen type III glomerulopathy. A new idiopathic glomerular disease.
E. Imbasciati, G. Gherardi, C. Coltuni, A. Sidoti, K. Morozumi, F.
Gudat, R. Epper, V. Basler, M.J. Mihatsch, Nephrology and Pathology
Unit, Sondnio Hospital and Institut of Pathology, University of Base!,
Basel, Switzerland. A new type of glomerular disease is reported in a
49-year-old Italian woman who presented with uncharacteristic renal
symptoms: hypertension and proteinuria. Clinical investigation ex-
cluded a familial renal disease and more specifically nail patella syn-
drome. By light microscopy a renal biopsy showed enlarged and
lobulated glomeruli. Mesangial areas and peripheral basement mem-
branes were massively expanded by the accumulation of an undefined
material which was negative with HE, PAS, PASM and Congo Red and
strongly positive with aniline blue. Cell proliferation was lacking.
Standard immunofluorescence techniques showed focal and segmental
depositis of immunoglobulmns in few glomeruli. By electron microscopy
the material was non-homogeneous, partly granular, partly fibnllar and
contained typical collagen fibers. The latter were identified by immu-
nohistochemical techniques as collagen type III, and to a lesser extent,
collagen type I. Review of the literature resulted in 12 similar or
identical cases reported from Japan and one additional case in a white
American female. Evidence of systemic disease is lacking. Most
patients develop nephrotic syndrome and progressive deterioration of
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renal function. Collagen type III glomerulopathy is suggested as the
term of this new type of idiopathic glomerular disease.
Measurements were made before (PreHD) and immediately after dial-
ysis (PostHD) and 4, 8, 24, 48 hours after the end of dialysis session.
Muscle protein and ammo acid (AA) metabolism in chronic renal
failure (CRF). G, Garibotto, R. Russo, P. Ancarani, M.R. Sala, P.
Moscateili, G. Deferrari, A. Tizianello, Divisions of Nephrology and
Clinical Methodology, University of Genoa, Italy. Muscle protein
turnover and AA exchange were studied in 7 patients with CRF (GFR
22 2 mI/mm) and in 7 controls in the postabsorptive state by using the
forearm perfusion method together with the systemic infusion of
3H-Phe. After a 150 mm primed tracer equilibration period, blood
samples were taken simultaneously from a brachial and a deep forearm
vein. Blood flow was measured by the cardio-green method, AA in
whole blood by an AA analyser, Phe and branched-chain ketoacids
(BCKA) in plasma by HPLC. Forearm volume was measured by water
displacement. Muscle protein synthesis and breakdown are expressed
as rates of Phe uptake and release. Data are given in nmol/min 100 ml
forearm. In CRF: a) protein breakdown is increased (60 3 vs. 44 3
in controls, P < 0.01) and associated with a parallel increase in protein
synthesis (42 3 vs. 27 3, P < 0.01); b) protein breakdown is
inversely related to arterial pH (P < 0.02); c) net release of Phe (18
2 vs. 17 3), Tyr (20 5 vs. 17 4) and Lys (42 9 vs. 45 9) is not
different from controls; d) also total AA release is unchanged (688 34
vs. 678 20): e) the release of Leu and Val and BCKA, mainly KIC, is
reduced (P < 0.05-0.025); t) Ser uptake disappears (7 7 vs. 22 6).
In conclusion, in postabsorptive patients with CRF, well before the
uremic stage, an increased protein breakdown associated with meta-
bolic acidosis takes place; net proteolysis is unaffected. Alterations in
BCAA metabolism suggest the occurrence of an increased BCAA
degradation proceeding beyond the transamination step.
Effect of a vegetarian soy diet on nephrotic syndrome. M.G. Gentile,
G. D'Amico, G. Manna, R. Ciceri, F. Cofano, G. Fellin, Division of
Nephrology, San Carlo Hospital, Milan, Italy, Dietary therapy is the
most rational and harmless approach for controlling persistent hyper-
lipidemia in nephrotic patients. Recent experimental data suggest that it
might also reduce urinary protein loss, but its efficacy has never been
systematically tested. After a baseline control period on a free diet, 20
untreated pts with chronic glomerular diseases, stable long-lasting
severe proteinuria (5.9 0.7 g124 hrs) and hyperlipidemia [mean serum
cholesterol (C) 333 29 mg/dl] were given a vegetarian soy diet for
2 months, which was low in fat (28% of total calories) and in proteins
(0.71 0.08 g/kgofidealbody wt/day), free of cholesterol, P/S acid fats
> 2, and in fiber (40 g/day). At the end of the diet period for two more
months all patients resumed a free diet of the baseline period (wash-out
period). The soy diet induced a highly significant decrease in total
serum C (28%), LDL-C (32%), HDL-C (14%), apolipoprotein B (19%),
apolipoprotein A (8%), phospholipids (21%) and urinary protein excre-
tion (33%), without significant change in serum tryglicerides. The levels
of all lipid fractions and the amount of proteinuria tended to return
toward the baseline value after discontinuation of the dietary regimen.
This study demonstrates that a low protein vegetarian soy diet can
control serum lipid abnormalities of nephrotic patients as Ca effi-
ciently as the lipid-lowering agents, and is also able to induce a
reduction in proteinuria.
Thirst in hemodialysis patients: hormonal and hemodynamic features.
G. Graziani, A. Morganti, A. DeiBo, G. Ambroso, S. Badalamenti, E.
Viganô, frI. Marabjni, 5, Casati, C. Ponticelli, Divisione di Nefrologia
e Dialisi, IRCCS Ospedale Maggiore, and Clinica Medica Universitd di
Milano, Milan, Italy. Many hemodialysis patients (pts) suffer from an
excessive thirst which leads to an abnormal interdialytic weight gain
with related clinical consequences. To elucidate the mechanism of this
abnormal thirst, we compared plasma concentration of dipsogemc
hormones [Vasopressin (ADH), angiotensin II (Ang II)], mean arterial
pressure (MAP), heart rate (HR) in two groups of hemodialysis pts. The
first group included 7 drinker pts (D) with an interdialytic weight gain
above 11% of total body water (range 11—16%), the second group (C)
included 6 pts with an interdialytic weight gain of 7% (range 6—8%).
PreHD PostED 4 hr 48hr
Ang II D 51 34 103 fi4 136 l12 59 44
pg/mi C 14±7 12±8 12±8 13±10
ADH D 5.7 1.9 10.6 8.8 5.9 2.4 5.7 1.6
pg/mi C 6.1 3.4 14.8 15.6 4.9 2.8 3.7 1.8
MAP D 97 14 86 16 91 16 100 14
mmHg
HR
bpm
C
D
C
99±6
84 12b
60±6'
83±15
98 19b
71±14'
98±20
91 l9'
64±8'
100±13
81 Ii"
61±8'
ANOVA: a P <0.0001; b p <0.001; 'P <0.006
Conclusions: Pts of group D had significantly higher plasma Ang II
levels than pts of group C during the whole interdialytic period. Plasma
ADH levels were above the normal values without difference between
the two groups, therefore, the two groups of hemodialysis pts had
different neuro-hormonal patterns. Our results suggest that elevated
Ang II and HR in group D can be considered as a homeostatic
mechanism triggered by the sympathetic activation to maintain MAP
and effective blood volume. These plasma levels of Ang II are well
above the dipsogenic range and may thus contribute in stimulating the
thirst in group D patients.
Fish oil supplementation in hemodialysis patients: Effects on lipid
composition and peroxidation in red blood cell membranes. G. Panzetta,
0. Olivieri, S. Ferrari, Divisione Clinicizzata di Nefrologia, Istituto di
Patologia Medica, Istituto di Chimica e Microscopia Clinica; Univer-
sitd degli, Studi di Verona, Verona, Italy. In view of the high preva-
lence of cardiovascular disease in hemodialysis patients we performed
a study to determine whether lipid composition of cell membranes can
be modified by fish oil administration (30 ml a day for 60 days) rich in
EPA (1.27 glday) and DOHA (1.7 g/day). Eleven stable non-diabetic
patients (4M, 7F), 35 to 70 years old, on conventional dialysis treatment
(4 hr 3X a week) from 58 42 months were included; 11 well-matched
dialysis patients constituted the control group. Since fish oil supplemen-
tation could also affect the susceptibility to lipid peroxidation, we
determined the RBC levels of malonyl-dialdehyde acid (MDA), gluta-
tion peroxidase (GSH-PX) and superoxide dismutase (SOD) activity.
Lipid profile was characterized by an increase in mono-unsaturated
fatty acids and a decrease in the n-3/n-6 fatty acid ratio, due to both high
levels of arachidonic acid and low levels of EPA and DOHA in RBC
membranes. Fish oil supplementation was followed by a normalization
of arachidonic acid content (from 23.2 1.5% to 19.4 1.6%; P <
0.001) and an increase in the n-3/n-6 ratio (from 0.24 0.04 to 0.43
0.09; P < 0.003), No significant variations in lipid composition were
observed in the control group. Erytrocyte MDA production was found
increased after fish oil supplementation (from 826 71 to 893 91
j.mol/g Hb; P < 0.01), while GSH-PX was unchanged and SOD activity
was slightly stimulated (from 8298 2204 to 10558 2210 IU/g HB; P
<0.022). These results show that fish oil is effective in normalizing lipid
composition in cell membranes of dialysis patients; however, they also
suggest that an increase in the susceptibility to lipid peroxidation could
be a side effect of fish oil therapy.
Parameter estimator and adaptive controller to regulate intradialytic
blood volume trends. A. Santoro, M. Spongano, E. Mancini, M. Rossi,
F. Paolini, P. Zucchelii, Divisione di Nefrologia Ospedale Malpighi,
Bologna, Hospal-Dasco, Medolla, Italy. Dialysis-induced hypovolemia
is one of the main pathogenetic factors in determining intra-dialytic
cardiovascular instability. In order to match the blood volume (BV)
intradialytic trends with the desired trajectories and profiles, we have
developed an automatic control system, called BVAC, which is based
upon a mathematical model with adaptive control. The BVAC is made
up of 3 subunits: I) a noninvasive optic probe which assesses the BV
variations, deriving them from hemoglobin changes; 2) a dialysis
machine with a two-directional interface linked to 3) a personal com-
puter on which a linear, second order, time-dependent mathematical
model is implemented. The model is based upon a dynamic regulator
able to continuously evaluate the coefficients between UF and BY
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variations, and thus set new UF values that can bring about the desired
BV trends. The system was tested in vivo in 4 patients for a total of 44
sessions modelled according to pre-defined BY trajectories. In 78% of
the cases there was a near perfect fit (1% mean difference) between the
pre-set BY curves and the ones obtained experimentally, even taking
into account the constraints of treatment duration and the patient's
weight loss. In conclusion, BYAC seems to be a worthwhile system for
the control of intradialytic volemia. However, further clinical studies
are necessary to determine how "intradialytic blood volume control"
interacts to reduce dialysis-related cardiovascular instability.
Lymphocytic phenotype and monocytes in uremic subjects: Non-re-
sponders to HBS recombinant vaccination. G. Sanna, V. Fanelli, M.
Ganadu, P. Lodde, G. Cherchi, P. Tilocca, L. Calvisi, Servizio Nefro-
logia e Dialisi; Direzione Sanitaria; Laboratorio Analisi; Ospedale
Antonio Segni Ozieri, Italy. In the 1980's there was a widespread use of
plasma derived vaccines (Pasteur M.S.D.) for prophylaxis of hepatitis B
in hazard-prone subjects. Among the ESRD patients a high percent of
no responders (NR) (35%—58%) have been found in spite of double
doses or different schedules. The purpose of this study was to evaluate
the effectiveness of recombinant vaccine. To assess elements of NR,
pre-identification based on immune-related parameters we studied 19
HD patients and 15 healthy controls (C) who were given 3 doses,
respectively, 40 and 20 jig, of recombinant DNA hepatitis B vaccine
(Engerix-B S.K.F.) at an interval of 0, 1, and 6 months. Samples were
taken before every single dose and 2 months after the third. We
estimated the T lymphocyte subsets (OKT3, OKT4, OKT8), T4/T8 ratio
and the peripheral leucocyte changes.
1 P 2 P
Tit. Pts 7.0 1.4 NS 15.4 11.9 NS
p/n (%) 0/19 (0) 3/19 (17.6)
P NS 0.005
Tit. C 8.0 3.4 0.001 87.9 52.4 NS
p/n (%) 1/15 (6.6) 12/15 (80)
6 P 8
Tit. Pts 21.4 16.1 0.001 228.7 119.7
p/n (%) 5/17 (29.4) 11/17 (64.7)P 0.007 NS
Tit. C 125.8 92.1 0.001 311.5 105.9
p/n (%) 13/13 (100) 3/13 (100)
The immunization of C and responders (R) at 8 months seemed higher
than previous reports after 3 doses; in the R subjects the recall dose at
6 months seems to be the determinant. In the NR we found some
distinctive features that suggested the possibility of pre-identification of
these subjects: a higher number of leucocytes (8233 vs. 693l/pi, P <
0.01) and monocytes (relative 8.3% vs. 5.7%, P < 0.0001, and absolute
658/jzi vs. 396/jd, P < 0.004); a lower percent of OKT4 (37.5% vs.
42.6%, P < 0.004) and lower values of T4/T8 ratio (NS) even in the
normal range. In NR the percent of T circulating (OKT3), different from
R, was inversely correlated to dialytic age (r = 0.723, P < 0.001). A
specific immune therapy in respect of cost benefit ratio and in preven-
tive terms may be reserved for them.
Clinical significance of ANCA in idiopathic crescentic glomerulonephri-
tis: A clinical histological study in 14 cases. F. Ferrario, P. Napodano, A.
Giordano, R.A. Sinico, M.T. Porn, E. Gandini, E. Sabadini, G.
D'Amico, Division of Nephrology, S.Canlo Hospital, Milan, Italy. To
study the clinical significance of ANCA in pauci-immune idiopathic
crescentic glomerulonephritis (50% of cellular crescents), we reviewed
the clinical-morphological findings in 14 cases. According to ANCA
positivity (detected by indirect IF and Elisa) the pts were divided into
two groups: Group 1(8 cases), ANCA positive pts (all with a P-ANCA
pattern and anti-mpo Abs); Group II (6 cases) ANCA negative pts.
Group I and II were not different for age at renal biopsy (mean 63.7 vs.
57.3 years), onset of nephropathy (ARF 100%, mean Sr 7.6 vs. 8.3
mg/dl) percentage of crescents (92.5 vs. 71.6). Group I and II signifi-
cantly differed in sex (Group I F 100%—Group II M 100%), proteinuria
(mean 1.7 vs. 4.1 g/24 hr) and histological features: a) intracapillary
necrosis (100% vs. 0), b) presence of renal vasculitis (50% vs. 0), c)
interstitial infiltrates (100% vs. 50%—massive and periglomerular 62%
vs. 16%). We conclude that ANCA positivity can differentiate 2 groups
within pts with idiopathic RPGN: a necrotizing form, with a female
prevalence and anti-MPO antibodies, which probably share pathoge-
netic mechanisms with systemic vasculitis, and a non-necrotizing form
where other unidentified mechanisms are implied.
Causes of death in vasculitis. P. Stratta, C. Canavese, A. Thea, M.
Dogliani, M. Ferrero, G. Mazzucco, G. Monga, A. Vercellone, Depart-
ments of Nephrology and Human Pathology, University of Torino,
Torino, Italy. Despite improvement in patient survival achieved by
more aggressive therapies in vasculitis, the choice of the optimal
protocol is still a problem due to the severity of disease, and to caution
suggested by the often aged patients with acute renal failure (ARF). A
review of 58 cases of vasculitis (37 m, 21 f, mean age 54.4 years, range
22 to 78 years) observed from 1975 to 1991 shows that early death (<I
year from diagnosis) occurred in 21 of 58 patients (36%). However,
early deaths were observed only in cases with ARF (44), thus reaching,
in this subgroup, the rate of 48%. Causes of death from autoptic (N
11) or clinical data (N = 10), were: infection in 4 (19%), cardiovascular
accident in 7 (33%), and persistent activity of disease in 10 (48%). By
grouping patients with ARF according to different treatments, the
number of deaths was 5 of 7 (71%), 6 of 9 (67%), and 10 of 28 (36%),
respectively, in patients treated with supportive therapy only (A),
steroid alone (B), or steroids + other immunodepressor agents (C).
Infection accounted for 40% in A, 17% in B, and 10% in C, respectively;
persistent activity of disease accounted for 40% in A, 33% in B, and
60% in C, respectively. The main conclusions are: 1) ARF as clinical
sign of presentation has a bad prognostic value in vasculitis; 2)
persistent activity of disease is the more frequent cause of death in
vasculitis despite aggressive treatment; 3) infection is not a common
cause of death even in aged patients with ARF who are treated by
aggressive protocols.
Clinical significance of ANCA in idiopathic crescentic glomerulonephri-
tis: A clinical histological study in 14 cases. F. Ferrario, P. Napodano, A.
Giordano, R.A. Sinico, MT. Porn, E. Gandini, F. Sabadini, G.
D'Amico, Division of Nephrology, S.Carlo Hospital, Milan, Italy. To
study the clinical significance of ANCA in pauci-immune idiopathic
crescentic glomerulonephritis (50% of cellular crescents), we reviewed
the clinical-morphological findings in 14 cases. According to ANCA
positivity (detected by indirect IF and ELISA) pts were divided into
two groups: Group 1(8 cases), ANCA positive pts (all with a P-ANCA
pattern and anti-mpo Abs); Group II (6 cases) ANCA negative pts.
Group I and II were not different for age at renal biopsy (mean 63.7 vs.
57.3 years), onset of nephropathy (ARF 100%, mean Scr 7.6 vs. 8.3
mg/dl) percentage of crescents (92.5 vs. 71.6). Group I and II signifi-
cantly differed in sex (Group I F lOO%—Group II M 100%), proteinuria
(mean 1.7 vs. 4.1 g/24 hr) and histological features: a) intracapillary
necrosis (100% vs. 0), b) presence of renal vasculitis (50% vs. 0), c)
interstitial infiltrates (100% vs. 50%, massive and periglomerular 62%
vs. 16%). We conclude that ANCA positivity can differentiate two
groups within pts with idiopathic RPGN: a necrotizing form, with a
female prevalence and anti-MPO antibodies, which probably shares
pathogenetic mechanisms with systemic vasculitis, and a non-necrotiz-
ing form where other unidentified mechanisms are implied.
